LENZ Therapeutics, Inc. (LENZ) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Lenz Therapeutics, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.057 Good afternoon, ladies and gentlemen, and welcome to the Lens Therapeutics First Quarter 00:00:05.057 -- 00:00:10.664 2025 Financial Results Conference Call. At this time, all participants 00:00:10.664 -- 00:00:15.790 are in a listen-only mode. Following prepared remarks from management, we will conduct 00:00:15.790 -- 00:00:20.236 a question-and-answer session, and instructions will follow at that time. 00:00:20.236 -- 00:00:22.699 As a reminder, this call is being recorded. 00:00:22.699 -- 00:00:28.145 At this time, I would like to turn the call over to Dan Chevalard, Chief Financial 00:00:28.145 -- 00:00:31.387 Officer. Please go ahead. 00:00:32.684 -- 00:00:35.967 Thank you. Good afternoon, and thank you for joining us today. 00:00:35.967 -- 00:00:40.872 My name is Dan Chevalard, Chief Financial Officer of Lens Therapeutics. 00:00:40.872 -- 00:00:45.236 We are joined today by Abe Schimeltenich, our President and Chief Executive Officer, 00:00:45.236 -- 00:00:48.940 and Sean Olson, our Chief Commercial Officer, as well as Dr. 00:00:48.940 -- 00:00:55.226 Mark Odrich, Chief Medical Officer, who will join us for the question and answer session. 00:00:55.226 -- 00:00:59.049 Before we begin, I would like to remind you that this call will contain forward-looking 00:00:59.049 -- 00:01:04.432 statements regarding Lens's future expectations plans, prospects, 00:01:04.432 -- 00:01:09.197 corporate strategy, regulatory and commercial plans and expectations, 00:01:09.197 -- 00:01:12.820 cash runway projections, and performance. 00:01:12.820 -- 00:01:18.026 Actual results may differ materially from those indicated by these forward-looking statements 00:01:18.026 -- 00:01:22.330 as a result of various important factors and risks, including t...